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====

Of the approximately 335 emerging infectious diseases that were identified between 1940 and 2004, 60.3% originated in wildlife^[@CR1]^. From past pandemics, it is clear that highly pathogenic zoonoses are major threats to global human health, economic stability and national security^[@CR1],[@CR2],[@CR3],[@CR4]^. SARS-CoV and swine influenza virus CA/04/09 H1N1 have caused substantial human morbidity and mortality in the 21st century. Similar to influenza, CoVs have a strong history of host shifting and cross-species transmission^[@CR5],[@CR6]^. In addition to the emergence of SARS-CoV in 2002, which caused 50% mortality in aged populations, several other human CoVs, such as HCoV-NL63, HCoV-OC43 and HCoV-229E, probably emerged from animal reservoirs within the past 200 years^[@CR7],[@CR8]^. The sudden emergence of new respiratory viral pathogens from animals underscores the need for new, broadly applicable vaccine strategies that rapidly and rationally attenuate emerging zoonoses, especially to protect vulnerable populations in future outbreaks.

Vaccines have a long history of success in reducing viral disease burdens. Live, attenuated viruses are ideal vaccine candidates, as they elicit balanced innate and adaptive lifelong protective immune responses with low production and delivery costs^[@CR9]^. Unfortunately, broadly applicable strategies for the rational design of live, attenuated virus vaccines have remained elusive, and vaccines attenuated by chemical treatment or passage can revert to virulence, resulting in disease outbreaks in unvaccinated and immunocompromised populations^[@CR9]^. Moreover, the precise mechanism of attenuation often remains unclear; thus, the stability of the attenuation cannot be clearly evaluated or assured.

RNA viruses encode RNA-dependent RNA polymerases that lack efficient proofreading capabilities; the resulting high error rates, which range from 10^−3^ to 10^−5^ mutations per site per round of replication, render RNA viruses highly vulnerable to lethal mutagenesis using chemical agents^[@CR10],[@CR11]^. High mutation rates generate considerable genomic diversity, allowing RNA viruses to rapidly adapt to changing environmental conditions and hosts^[@CR12]^. Increased replication fidelity has been shown to reduce the virulence of poliovirus and chikungunya virus^[@CR12],[@CR13],[@CR14]^ and has been proposed as a strategy for live, attenuated virus design^[@CR15]^. CoVs encode the largest known RNA virus genomes (26--32 kb), exceeding the theoretical limits of viable RNA genome size^[@CR11]^. Mutation rates are lower in CoVs than in other RNA viruses, approaching 2 × 10^−6^ mutations per site per round of replication^[@CR16]^. Nsp14, encoded in the viral replicase gene, contains a 3′→5′ exoRNase (ExoN) of the DEDDh exonuclease superfamily^[@CR17]^. In addition to the CoVs, ExoN homologs are present in the members of the Nidovirales order, whose genomes are \>20 kb, but are not present in the smaller arteriviruses (with genomes of 12--16 kb), suggesting that the ExoN had a crucial role in genome expansion^[@CR16],[@CR18]^. *In vitro*, 3′→5′ exoRNase activity has been demonstrated for recombinant SARS-CoV nsp14 (ref. [@CR19]). We have engineered and recovered viable ExoN inactivation mutants from mouse hepatitis virus (MHV-ExoN) and SARS-CoV (Urbani background, SARS-ExoN). Both MHV-ExoN and SARS-ExoN inactivations are maintained stably for more than ten passages *in vitro* and have 15- to 20-fold increased mutation frequencies compared to wild-type MHV and SARS-CoV^[@CR16],[@CR20]^. Thus, ExoN has a crucial role in CoV RNA genome replication fidelity *in vitro*, probably by directly mediating or stimulating proofreading, a function previously unknown among RNA viruses^[@CR21]^.

In this study, we used the stable, low-fidelity mutator phenotype of the SARS-CoV ExoN mutants to determine whether decreased replication fidelity could be used as a rational design strategy for a live, attenuated vaccine with broad potential applications to other viruses^[@CR16],[@CR20],[@CR21]^. We evaluated (i) the impact of the inactivation of an RNA-proofreading exonuclease and the resultant mutator phenotype on CoV replication, fitness and pathogenesis; (ii) virus stability after passage or persistence *in vivo*; and (iii) the efficacy of using a decreased-fidelity mutant as a vaccine. Further, we assessed the potential for generating stably attenuated, reversion-resistant, immunogenic strains of known and newly identified CoVs to be used as vaccines in both immunocompetent and immunocompromised populations.

Results {#Sec2}
=======

The mutator phenotype and decreased fitness of MA-ExoN {#Sec3}
------------------------------------------------------

We engineered nsp14 ExoN inactivation mutations into the background of the virulent mouse-adapted SARS-CoV (MAwt), yielding MA-ExoN ([Fig. 1a,b](#Fig1){ref-type="fig"}). We compared MAwt, which causes increased mortality and acute respiratory distress in young and aged mouse models^[@CR22],[@CR23],[@CR24]^, and MA-ExoN in *in vitro* growth experiments (multiplicity of infection (MOI) = 0.1 PFU per cell). MA-ExoN showed a stable growth defect of less than 1 log ([Fig. 1c](#Fig1){ref-type="fig"}). When placed in direct competition, MA-ExoN was clearly less fit than MAwt over successive rounds of infection ([Supplementary Fig. 1a,b](#MOESM2){ref-type="media"}). At 6 h after infection (p.i.), MA-ExoN genome RNA levels were roughly equivalent to those of MAwt and were lower than those of MAwt at 12 h p.i.; by 24 h p.i., MA-ExoN genome RNA levels were approximately 10% of those of MAwt ([Supplementary Fig. 1c](#MOESM2){ref-type="media"}). Thus, the data suggest that MA-ExoN is able to initiate and establish replication efficiently through times of peak RNA synthesis (0--6 h) but has impaired accumulation, which manifests late in one round of infection and is amplified over multiple rounds. These results are consistent with accumulating defects resulting from a markedly increased mutation rate (see the Discussion section).Figure 1The nsp14 ExoN mutator virus in a virulent mouse-adapted SARS-CoV isogenic background.(**a**) Genome organization, with the locations of the nsp14 coding sequence (black rectangle) and the mouse-adapted mutations (triangles) shown. ORF1a/b, ORF1a and ORF1b. Structural proteins are labeled as follows: S, spike; E, envelope; M, membrane; N, nucleocapsid. (**b**) Nsp14 ExoN motifs, DEDD domain residues (underlined) and alanine substitutions (D90A and E92A) in motif I recovered in wild-type SARS-CoV and MAwt backgrounds. (**c**) Growth analysis (MOI = 0.1 PFU per cell) of wild-type SARS-CoV, S-ExoN, MAwt and MA-ExoN on Vero cells. Error bars, s.d. (**d**) Mutation frequency from complete genome sequencing of plaque isolates of MAwt and MA-ExoN (*n* = 5 for both) at passage 3. The increase in mean mutation frequency (horizontal lines) in MA-ExoN compared to MAwt (11.5×) is indicated. \**P* \< 0.01 (Mann-Whitney nonparametric test for independent samples). (**e**) The mutations identified with complete genome sequencing across five clones from each group. Filled circles, nonsynonymous mutations; open circles, synonymous mutations; black, noncoding mutations; red, mutations present in more than one clone; blue, mutations present in only one clone. Mouse-adapted mutations are shown as triangles on the genome schematic and were present in all sequenced genomes.

We then sequenced RNA from multiple MAwt and MA-ExoN plaques. Both the MAwt background and engineered ExoN mutations were present in all sequenced MA-ExoN clones. Additionally, MA-ExoN accumulated 14-fold more unique mutations and had a mean 11.5-fold greater mutation frequency compared to MAwt (*P* \<0.01) ([Fig. 1d,e](#Fig1){ref-type="fig"}). These results confirm that the growth and replication fidelity impairments of the nsp14 ExoN mutator phenotype are present in MA-ExoN and are indistinguishable from those in SARS-ExoN during replication in culture.

MA-ExoN is attenuated *in vivo* {#Sec4}
-------------------------------

To assess MA-ExoN virulence, we infected young (10-week-old) and aged (14-month-old) female BALB/c mice with MA-ExoN or MAwt ([Fig. 2](#Fig2){ref-type="fig"}). Young mice infected with MAwt showed dose-dependent weight loss and recovery ([Fig. 2a](#Fig2){ref-type="fig"}), though they had no observable dose-dependent differences in lung titers or clearance after day 4 p.i. ([Fig. 2b](#Fig2){ref-type="fig"}). In contrast, young mice infected with MA-ExoN showed no signs of clinical disease and had high but not dose-dependent lung titers that were rapidly cleared by day 4 p.i. ([Fig. 2a,b](#Fig2){ref-type="fig"}). We then compared MA-ExoN and MAwt infection in aged, immunosenescent mice^[@CR25]^. Mice infected with either virus experienced dose-dependent weight loss ([Fig. 2c](#Fig2){ref-type="fig"}); however, although lung titers were equivalent across all doses of MA-ExoN and MAwt on day 2 p.i., mice infected with MA-ExoN cleared the virus independent of inoculation dose, whereas mice infected with MAwt had begun to clear the virus from higher-titer infections more efficiently at day 4 p.i. than from lower-titer infections ([Fig. 2d](#Fig2){ref-type="fig"}). Additionally, whereas aged mice infected with MA-ExoN had no mortality, MAwt-infected mice had dose-dependent mortality ([Fig. 2e](#Fig2){ref-type="fig"}). As described previously^[@CR23]^, we found little if any virus in other organs. These experiments demonstrate that MA-ExoN is attenuated in both young and aged diseased mice compared to virulent MAwt and that disease symptoms, when present, are less pronounced in MA-ExoN infections than MAwt infections.Figure 2Weight loss and lung titer in BALB/c mice.(**a**--**e**) MA-ExoN and MAwt infections of 10-week-old (**a**,**b**) and 12- to 14-month-old (**c**--**e**) female BALB/c mice. (**a**,**c**) Weight loss. Dark shapes and solid lines, MA-ExoN; white shapes and dashed lines, MAwt; diamonds, 10^2^ PFU; squares, 10^3^ PFU; triangles, 10^4^ PFU. Error bars indicate s.d. (**b**,**d**) Lung titers. The titer for each mouse lung is indicated by an open circle; the mean titer of all mice at each time point is indicated by a horizontal bar. Days p.i. are indicated on the *x* axes; 2log, 3log and 4log indicate the MOIs of each virus (10^2^, 10^3^ or 10^4^ PFU, respectively). (**e**) Survival within aged mouse groups, calculated as the percentage of surviving mice compared to the total number of mice remaining on each day of the experiment. Line weights and symbols are as in **a** and **c**.

A potential concern with live, attenuated vaccines is the chance that they could revert to virulence *in vivo*, particularly in immunocompromised individuals. Therefore, we assessed whether MA-ExoN was attenuated in immunocompromised mice. We used MAwt and MA-ExoN to infect young *Rag*^−/−^ (recombination activating gene), severe combined immunodeficiency (SCID) and *Stat1*^−/−^ (signal transducer and activator of transcription 1) mice, as well as background controls (C57BL/6, BALB/c and 129 mice, respectively). All MA-ExoN--infected mice had significantly less weight loss than MAwt-infected mice (*P* \< 0.05; [Fig. 3a--c](#Fig3){ref-type="fig"} and [Supplementary Table 1](#MOESM2){ref-type="media"}). Only *Stat1*^−/−^ mice had any notable weight loss (∼15%) as a result of MA-ExoN infection; however, these mice did not pass experimental morbidity thresholds ([Fig. 3c](#Fig3){ref-type="fig"}). In contrast, all MAwt-infected *Stat1*^−/−^ mice died or were moribund by day 9 p.i., but MAwt infection was not lethal in C57BL/6 or 129 control mice ([Fig. 3a,c](#Fig3){ref-type="fig"}), as has been previously reported^[@CR22],[@CR26]^. *Rag*^−/−^ and SCID mice maintained detectable amounts of MAwt and MA-ExoN virus for 14 d (*Rag*^−/−^) or 60 d (SCID) beyond the background controls ([Fig. 3d,e](#Fig3){ref-type="fig"}) but showed no signs of illness over the course of the experiment despite a lack of viral clearance, expanding earlier reports from our laboratory that MAwt does not clear from *Rag*^−/−^ mice^[@CR26]^. The rapid clearance of MA-ExoN infection from *Stat1*^−/−^ mice ([Fig. 3f](#Fig3){ref-type="fig"}) further supports the hypothesis that clearance of SARS-CoV infection is dependent on both B and T cells^[@CR27]^.Figure 3Weight loss and lung titer in young immunocompromised mice.(**a**--**c**) MA-ExoN and MAwt infections of 10-week-old *Rag*^−/−^ (**a**), SCID (**b**) and *Stat1*^−/−^ (**c**) mice. C57BL/6 (**a**), BALB/c (**b**) and 129 (**c**) mice were included as background controls. Weight loss is shown. Dark shapes and solid lines, immunocompromised mice; white shapes and dashed lines, background control mice; circles, MA-ExoN; squares, MAwt. Error bars indicate s.d. (**d**--**f**) Lung titers for *Rag*^−/−^ (**d**), SCID (**e**) and *Stat1*^−/−^ (**f**) mice and background controls. The titer of each mouse lung is indicated by an open circle; the mean of all titers at each time point is indicated by a horizontal bar. Days p.i. are indicated on the *x* axes.

Mutation accumulation during persistent *in vivo* infection {#Sec5}
-----------------------------------------------------------

Infection with both MAwt and MA-ExoN persisted for at least 60 d in SCID mice ([Fig. 3e](#Fig3){ref-type="fig"}), potentially allowing for the most longitudinal cycles of replication and lowest immune barriers to the emergence of mutations conferring increased fitness, reversion to virulence and fidelity-compensating changes of any of the groups examined. To test this, we sequenced viral genomes from viral plaques grown from SCID mouse lung homogenates at 30 d p.i. ([Fig. 4](#Fig4){ref-type="fig"} and [Supplementary Table 2](#MOESM2){ref-type="media"}). We identified a total of 14 consensus mutations (∼100,000 nt) for MAwt, with 3 mutations shared in two or three genomes, resulting in 11 distinct mutations (4 synonymous and 7 nonsynonymous). For MA-ExoN, the engineered inactivation mutations were maintained. In contrast to MAwt, MA-ExoN plaques contained a total of 91 mutations (89 distinct: 32 synonymous and 57 nonsynonymous), corresponding to a 9.6-fold higher total mutation accumulation compared to MAwt.Figure 4Mutation accumulation in infected SCID mice at 30 d.p.i.The SARS-CoV genome is depicted at the top. The nsp14 ExoN coding region is denoted by a purple box, with the inactivating amino acid changes indicated above the schematic. The receptor-binding domain (RBD) is denoted by a black box. Individual SCID mouse genome sequences are represented by black horizontal lines. Dashed lines separate the nonstructural protein sequences in ORF1 and downstream ORFs. Mutations are indicated by lollipop shapes colored as follows: blue, synonymous, unique to one sequence; light blue, synonymous, present in three sequences; red, nonsynonymous, unique to one sequence; green, synonymous, present in two sequences; purple, nsp14 ExoN inactivation mutations. Mutations that alter the size of an ORF are indicated by a red Δ (deletion) or a red S (stop codon). Genome sizes, ORF and nonstructural protein boundaries and mutation marker placements are approximate.

We compared mutation accumulations across two separate regions (open reading frame 1a (ORF1a), nucleotides 493--8603, and ORF1b, nucleotides 12915--16520; [Supplementary Figs. 2](#MOESM2){ref-type="media"} and [3](#MOESM2){ref-type="media"} and [Supplementary Table 2](#MOESM2){ref-type="media"}) for statistical determinations. Mutation accumulations were significantly higher in MA-ExoN--infected mice for both regions (*P* \< 0.01). Additionally, there was a mean 18.3-fold increased accumulation for MA-ExoN across the ORF1a region. When we normalized the accumulations of mutations per 10 kb, MA-ExoN mutation accumulations in the ORF1a compared to the ORF1b region were not significantly different (*P* = 0.340) but remained significantly increased compared to the accumulation in MAwt (*P* \< 0.001 for both ORF1a and ORF1b). We identified no new mutations in any of the three MA-ExoN plaques, suggesting no obligatory or consistent pattern of adaptation or mutational bias. The most prevalent mutation identified (C16999M) was also present in viral stocks as a polymorphism; however, its frequency in the viral population remained stable (∼40%) both *in vitro* and *in vivo* and in experiments with both BALB/c and SCID mice ([Supplementary Tables 2](#MOESM2){ref-type="media"} and [3](#MOESM2){ref-type="media"} and data not shown). The results from persistent ExoN infection over 30 d were consistent with the results from passage of SARS-ExoN virus in culture: the ratios of accumulation of unique mutations (MA-ExoN:MAwt) during replication in SCID mice ranged from ∼9.6:1 to 18.3:1, which is similar to the ratio measured between SARS-ExoN and SARS-CoV in culture^[@CR16]^.

MA-ExoN resists reversion to virulence *in vivo* {#Sec6}
------------------------------------------------

To test the resistance to reversion to virulence during passage *in vivo*, we subjected MAwt and MA-ExoN to both short and long serial passages (24 h and 72 h per passage, respectively) in aged BALB/c mice ([Fig. 5](#Fig5){ref-type="fig"}). In both groups, viral titer remained stable from passage to passage ([Fig. 5a,b](#Fig5){ref-type="fig"}); additionally, viral plaque phenotypes were preserved, and the ExoN-inactivating mutations and amino acid substitutions were maintained (data not shown). In contrast, whereas MAwt titer remained stable over the 24-h serial passage, mice inoculated with lung homogenates from the 72-h passage died by day 3 in passage 2 ([Fig. 5b](#Fig5){ref-type="fig"}). Although MA-ExoN titer remained stable over the 72-h passage, mouse weights did not decrease during infection after passage 1 ([Fig. 5c](#Fig5){ref-type="fig"}). Notably, there was no evidence of a gain of virulence with serial passage in the MA-ExoN pathogenesis model: when aged mice were infected with lung homogenates from each of the final 24-h and 72-h passages, mice infected with MA-ExoN passages lost no or little weight, and MAwt-infected mice became moribund ([Fig. 5d](#Fig5){ref-type="fig"}).Figure 5Virulence of passaged MA-ExoN and MAwt viruses.(**a**--**c**) MA-ExoN and MAwt serial infections of 12-month-old female BALB/c mice. Passages (P) are indicated on the *x* axes. (**a**) Serial passage after 24 h. (**b**,**c**) Serial passage after 72 h. (**a**,**b**) Lung titers are shown, with average titers indicated by bars. In the 72-h passage, MAwt-infected mice died by day 3 of passage 2; thus, the viruses were not passaged further. (**c**) Weight loss in the mice infected in the 72-h passage is shown. Error bars indicate s.d. (**d**) MA-ExoN (24-h passage 8 and 72-h passage 3) and MAwt (passage 1) infections of 12-month-old female BALB/c mice. Weight loss is shown. Error bars indicate s.d. (**e**) Infections of 10-week-old female BALB/c mice with MA-ExoN and MAwt population viruses isolated from SCID mice at 30 d p.i.; weight loss is shown. Dashed line, mock (PBS) inoculation; dark shapes and solid lines, MA-ExoN; white shapes and solid lines, MAwt. For each virus, lungs from three separate mice were harvested (mouse 1--mouse 3), and viruses were subsequently inoculated without plaque purification (population); circles, mouse 1 populations (pop 1); squares, mouse 2 populations (pop 2); triangles, mouse 3 populations (pop 3). (**f**) Weight loss in 11-month-old female BALB/c mice infected with MA-ExoN 2.1 (with C16999A) or MA-ExoN 3.1 (without C16999A) plaque isolates from SCID mice after 30 d of infection (SCID30). Squares, SCID30 MA-ExoN 2.1; circles, SCID30 MA-ExoN 3.1. Error bars indicate s.d.

To test whether persistent MA-ExoN infection could result in phenotypic reversion to virulence, we used viruses harvested from SCID mice at day 30 p.i. to infect young BALB/c mice ([Fig. 5e](#Fig5){ref-type="fig"}). MAwt-infected mice showed signs of morbidity (weight loss, hunched posture and ruffled fur) but recovered. In contrast, MA-ExoN--infected mice showed no clinical signs of illness, as in the initial infection ([Fig. 2a](#Fig2){ref-type="fig"}). Additionally, plaques containing different mutational subsets were identically attenuated after re-infection of BALB/c mice ([Fig. 5f](#Fig5){ref-type="fig"}). These results demonstrate that after 30 d of persistent infection, the ExoN mutator phenotype did not revert to virulence despite the greatly increased mutation rate and population diversity.

MA-ExoN vaccination protects mice from lethal challenge {#Sec7}
-------------------------------------------------------

Aged mice mount poor productive immune responses to SARS-CoV vaccines and remain highly susceptible to severe disease and lethal infection^[@CR24],[@CR28]^, thus representing the most sensitive means to measure vaccine efficacy against lethal SARS-CoV infection. To test the efficacy of the MA-ExoN mutant as a possible vaccine against lethal challenge, we vaccinated aged BALB/c mice with MA-ExoN and allowed them to recover from infection. We then challenged the mice with a lethal dose of MAwt ([Fig. 6](#Fig6){ref-type="fig"}). Mock-vaccinated mice succumbed to MAwt challenge by day 3 p.i. and had high lung titers ([Fig. 6a,b](#Fig6){ref-type="fig"}); however, mice vaccinated with MA-ExoN were protected from illness ([Fig. 6a](#Fig6){ref-type="fig"}). Further, in contrast to other vaccine platforms^[@CR24],[@CR28],[@CR29]^, MA-ExoN--vaccinated mice had no detectable lung titers 2 d after challenge ([Fig. 6b](#Fig6){ref-type="fig"}).Figure 6MA-ExoN vaccination protects from lethal challenge.(**a**,**b**) Low-passage MA-ExoN and mock (PBS) vaccinations of 12-month-old female BALB/c mice followed by lethal challenge with MAwt. (**a**) Weight loss in challenged mice. Dark circles, 10^4^ PFU MA-ExoN vaccination; white circles, 10^2.5^ PFU MA-ExoN vaccination; dark triangles, PBS vaccination. Error bars indicate s.d. (**b**) Lung titers at day 2 after challenge. ExoN was given at a 2.5log (10^2.5^ PFU) vaccination. The mean titer is indicated by a bar in each group. (**c**) Fifty-percent plaque reduction neutralization titer (PRNT~50~) assay using sera from PBS-vaccinated and MA-ExoN--vaccinated mice to neutralize MAwt. Reciprocal dilutions capable of effecting 50% plaque reduction are shown by circles; mean reciprocal dilutions are indicated by a bar for each group. The limit of detection for each assay, if given, is indicated by a dashed line.

Additionally, mice vaccinated with MA-ExoN generated high amounts of neutralizing antibodies (mean, 1:311 ± 37.5 reciprocal 50% neutralization titer) ([Fig. 6c](#Fig6){ref-type="fig"}). The minimal neutralizing titers for protection against SARS-CoV infection in mice have been reported as 1:25--1:49 (ref. [@CR30]). Thus, even with a single vaccination, MA-ExoN provided complete protection against lethal challenge in a susceptible, immunosenescent mouse model of lethal SARS-CoV infection. To our knowledge, the MA-ExoN virus is the first approach to SARS-CoV immunization that fully protects against clinical disease and viral replication in an aged mouse model^[@CR24],[@CR28],[@CR29]^.

Discussion {#Sec8}
==========

Live, attenuated vaccines have substantially reduced the global disease burden associated with viral infections, including, for example, those of measles, mumps, rubella, polio, yellow fever and chickenpox^[@CR9],[@CR15]^. However, live, attenuated vaccines carry several risks, including primary or secondary reversion to a virulent phenotype, as in the case of poliovirus^[@CR9]^. In fact, attenuated phenotypes encounter natural selective pressures for reversion that can cause outbreaks of disease in unvaccinated populations^[@CR31]^.

RNA virus replication fidelity has evolved to balance genome diversity and stability; therefore, inactivating an enzyme, such as nsp14-ExoN, that is responsible for high-fidelity replication could theoretically drive the virus toward instability, deleterious mutational diversity and decreased fitness in complex environments, which we observed here *in vitro*. It is possible that nsp14-ExoN may have other functions in viral RNA synthesis^[@CR21]^; however, global impairment of viral RNA synthesis alone cannot explain the *in vitro* results and the attenuating phenotype *in vivo*.

It is not possible to fully separate defects caused by increased mutation load from those resulting from the replication defect observed, and both probably contribute to the phenotype. However, our results are consistent with the hypothesis that both stable and evolving defects resulting from the mutator phenotype have irrevocably attenuated MA-ExoN. These defects could include (i) mutations that impair or terminate translation, replication and transcription; (ii) mutations that impair or abolish protein functions; or (iii) changes in RNA polymerase processivity in the presence of an inactivated proofreading exonuclease. These combined impairments may be manifested with CoV ExoN mutants, as the high number of accumulated mutations per genome is unprecedented among viral mutator strains. Indeed, the phenotype observed with CoV ExoN inactivation is similar to those reported for other polymerase complexes with inactivated exonucleases, such as human mitochondrial DNA polymerase γ (pol γ)^[@CR32],[@CR33]^ and bacteriophage T7 DNA polymerase^[@CR34],[@CR35],[@CR36]^. In pol γ studies, the loss of proofreading was associated with impaired polymerase activity in a manner that was probably causal, impossible to uncouple and characterized by decreased speed, increased template dissociation and restricted access of nucleotides to the polymerase active site^[@CR32],[@CR33]^. For CoVs, the high levels of iterative amplification of both genomic and subgenomic RNA would further accelerate these deleterious processes by providing aberrant templates. The loss of ExoN proofreading would continuously generate new potentially attenuating alleles, and defective genomes and would reduce both genome fitness and the risks for primary and secondary reversions to virulence.

In this study, we demonstrate that MA-ExoN is attenuated in mice and that the mutant clears rapidly in the presence of an adaptive immune response. Although our *in vivo* experiments with MAwt recapitulated many of the phenotypes observed in aged and immunocompromised human populations, additional testing of MA-ExoN as a vaccine in primates will be necessary to further confirm its stability *in vivo*^[@CR37]^. Experiments in SCID mice with persistent MA-ExoN infection verified the accumulation of mutations across the genome without evidence for the selection of either phenotypic virulence-enhancing alleles or primary genotypic reversion. Viruses harvested after passage remained avirulent, supporting the conclusions that (i) selection for virulence is not occurring; (ii) selection is being outcompeted by the gradual accumulation of attenuating mutations in individual genomes or the population mutational swarm; or (iii) the mutant is unable to generate or select for either fast-growing or slow-clearing viruses that are also more virulent. Not surprisingly, we identified a limited number of polymorphisms in the MA-ExoN virus stock that we used in subsequent experiments. Viruses with and without these mutations were fully attenuated *in vivo*, and the mutations were also maintained in lungs in the same frequencies as in the virus stock, suggesting that they were not selected against during passage *in vivo*. Thus, no single mutation or polymorphism could be clearly linked to viral attenuation except for the ExoN inactivation.

Notably, we have shown that MA-ExoN vaccinations are completely protective against replication and lethal challenge in aged BALB/c mice, the SARS-CoV mouse pathogenesis model that captures most of the severe clinical disease outcomes in human infections. Additionally, neutralization titers were equivalent or superior to those reported in studies of two-dose alphavirus replicon S glycoprotein vaccines and killed vaccines containing alum, with the additional advantage of protecting against virus replication and clinical disease^[@CR24],[@CR28],[@CR29]^.

Live, attenuated vaccines must have two characteristics, aside from the capacity to elicit a protective immune response: resistance to primary reversion and stable attenuation at secondary sites. We have demonstrated that MA-ExoN has both of these characteristics. In all circumstances, the engineered inactivation mutations were maintained, indicating that exonuclease activity is not crucial for the virus life cycle and that the 4-nt, 2--amino acid change presents a substantial barrier to primary reversion; further, the passage experiments suggest that the virus lacks redundant or complementing mechanisms to fully restore the loss of ExoN activity. In addition, MA-ExoN harvested from persistently infected SCID mice retained an attenuated phenotype when re-inoculated into young BALB/c mice, suggesting that persistence does not select for virulence. Future studies are necessary to address whether additional modifications could enhance and stabilize the attenuated phenotype by reducing the likelihood of gain of function by homologous recombination, such as introduction of the ExoN inactivation in a background with rewired transcriptional regulatory sequences^[@CR38]^, which could increase resistance to reversion.

The inactivation of putative viral proofreading components in the pursuit of a stable vaccine constitutes a paradigm that has high potential to be broadly applicable to those members of the Nidovirales order with an exonuclease activity. In a time when metagenomics studies inform us of the likelihood of future viral emergence events---viruses that have the potential to afflict the human population much as SARS-CoV did in 2002--2003---the design and ready implementation of an attenuation strategy that can be rapidly applied to any emerging CoV potentially represents a major advance in the preservation of public health. These data should also encourage the pursuit of fidelity-impairing mutations in the replicase proteins of other RNA viruses as potential targets or the use of CoVs as vaccine vectors for rational vaccine design.

Methods {#Sec9}
=======

Construction of SARS D plasmid with ExoN and mouse-adapted mutations. {#Sec10}
---------------------------------------------------------------------

A SARS-CoV D plasmid was constructed by restriction digestion and ligation of existing SARS D--ExoNI^[@CR16]^ and SARS D mouse-adapted^[@CR23]^ plasmids. Briefly, both plasmids were restriction digested with BstB I and Xba I enzymes. After treatment of the digested SARS D--ExoNI plasmid with Antarctic Phosphatase (New England BioLabs, Ipswitch, MA, USA), fragments were isolated, purified and ligated together using T4 DNA Ligase overnight at 4 °C as described previously^[@CR39]^. Colonies were screened for proper insert size by restriction digestion and electrophoresis, and the presence of the appropriate mutations was verified by sequencing.

Generation of SARS-CoV MA-ExoN mutant virus. {#Sec11}
--------------------------------------------

Virus containing the ExoNI inactivation and mouse-adapted mutations within the viral coding sequence was produced using the infectious complementary DNA (cDNA) assembly strategy for SARS-CoV as previously described^[@CR39],[@CR40]^. ExoN viruses were kept at low passage (one passage past virus rescue, P1) to minimize the accumulation of mutations in cell culture. For this study, an equivalently low-passaged MAwt virus was used for comparison.

*In vitro* passage series and viral growth and plaque assays. {#Sec12}
-------------------------------------------------------------

MAwt and MA-ExoN viruses were grown in Vero cells at MOI = 0.1 PFU per cell in all *in vitro* experiments, with the exception of the genome RNA quantification experiment, which was performed at MOI = 3 PFU per cell. Passage series and growth experiments were performed, and viral titers were determined as previously described^[@CR16]^.

Competition assay. {#Sec13}
------------------

Vero cells were plated at 10^6^ cells per well in six-well plates. Cells were infected at an MOI of 0.1 with combinations of MAwt and MA-ExoN at 1:1, 1:10 and 1:100 ratios favoring either MA-ExoN or MAwt and were incubated for 24 h at 37 °C. After 24 h, 100-μl aliquots of each supernatant were passed to fresh six-well plates of Vero cells for five total successive passages, and infected monolayers were harvested in TRIzol (Invitrogen, Grand Island, NY, USA). After passages were complete, RNA was purified according to the manufacturer\'s protocol, and first-strand cDNA was generated as described^[@CR41]^. PCR products were produced using the primers S32F and S34R ([Supplementary Table 4](#MOESM2){ref-type="media"}). Once the presence of single-band PCR products was verified by agarose gel electrophoresis and the yields were calculated by spectrometry, 100 ng of each product was restriction digested using BsrF I, which cuts in the nsp14-ExoN engineered mutation site but not in the corresponding MAwt sequence. Digested products were resolved on a 1.7% agarose gel, and normalized relative percentages of MAwt and ExoN-MA digested products were calculated using ImageJ (<http://rsbweb.nih.gov/ij/>).

Quantification of genome RNA. {#Sec14}
-----------------------------

Vero cells were infected with either MAwt or MA-ExoN at MOI = 3 PFU per cell. At 6, 12 and 24 h p.i., RNA was harvested in TRIzol and isolated according to the manufacturer\'s protocol. First-strand cDNA was generated as described above, and real-time PCR was performed assessing for genome RNA using the primers 5′-AGCCAACCAACCTCGATCTCTTGT-3′ (forward) and 5′-TGACACCAAGAACAAGGCTCTCCA-3′ (reverse). cDNA was normalized using the GAPDH primers 5′-TGCACCACCAACTGCTTAGC-3′ (forward) and 5′-GGCATGGACTGTGGTCATGAG-3′ (reverse)^[@CR42]^. Normalized results were then compared as ratios of MA-ExoN to MAwt genomes using the ΔΔCt method.

Infection of mice with SARS-CoV MAwt and MA-ExoN. {#Sec15}
-------------------------------------------------

All experimental protocols involving mice were reviewed and approved by the institutional animal care and use committee at the University of North Carolina, Chapel Hill. The following groups of mice were used: 10-week-old female BALB/c (Charles River Laboratories, Wilmington, MA, USA), 14-month-old female BALB/c (Harlan Laboratories, Indianapolis, IN, USA), 10-week-old female *Stat1*^−/−^ (Taconic Farms, Hudson, NY, USA; stock 002045-M-F), 10-week-old female 129S6/SvEvTac (Taconic; stock 129SVE-F), 10-week-old female *Rag*^−/−^ (Jackson Labs, Bar Harbor, ME, USA; stock 002216), 10-week-old female C57BL/6 (Jackson; stock 00064) and 10-week-old female SCID (Jackson; stock 001803). Mice were lightly anesthetized and infected intranasally with varying doses (10^2^--10^4^ PFU, depending on the experiment) of SARS-CoV MAwt or SARS-CoV MA-ExoN. Mice were weighed daily, and on certain days specified in each experiment, a subset of mice in each group was euthanized, and their lungs were harvested for virus titer. Mice that dropped below 70% of their initial mass or were moribund were euthanized before their scheduled time points. Serial passages were inoculated as above for passage 1; subsequent passages were inoculated with 50 μl of clarified lung homogenate (lungs were homogenized in 1 ml of PBS) from the previous passage. All experiments used *n* = 5 mice per virus per dosage per condition (if applicable) per time point, with the exception of experiments using immunocompromised mice, in which *n* = 3.

Determination of virus titer in infected mouse lungs. {#Sec16}
-----------------------------------------------------

Lungs harvested for virus titer were weighed and homogenized in 1.0 ml PBS at 6,000 r.p.m. for 60 s in a MagnaLyser (Roche, Basel, Switzerland). Virus titers were determined by plaque assay on Vero cells as previously described^[@CR39]^.

Determination of viral neutralization antibody titers in mouse sera. {#Sec17}
--------------------------------------------------------------------

Mouse sera were heat inactivated for 30 min at 55 °C and then serially diluted to 1:100, 1:200, 1:400, 1:800 and 1:1,600 in PBS to a volume of 125 μl. Next, 125 μl of PBS containing low-concentration MAwt (40 PFU) or high-concentration MAwt (240 PFU) was added to each serum dilution. The virus-serum mixtures were incubated at 37 °C for 30 min. After incubation, virus titers of the mixtures were determined by plaque assay as described^[@CR39]^. We then calculated the PRNT~50~ values, the serum dilutions at which plaque formation was reduced by 50% relative to that of virus stock not treated with serum.

Viral genome sequencing. {#Sec18}
------------------------

To determine the sequences of viral genomes present in SCID mouse lungs after 30 d of infection, plaques were isolated from lung samples from SCID mice at 30 d p.i. as described above. Briefly, once individual, well-resolved viral plaques were visible, they were harvested by collecting the agarose plugs above them using a 200-μl pipette tip. Each agarose plug was dropped in 0.5 ml PBS, allowed to diffuse for 24 h at 4 °C and then applied to ∼70% confluent monolayers of Vero cells in T25 flasks and incubated for 48 h at 37 °C. Infected cell monolayers were then harvested in 1 ml TRIzol. First-strand cDNA was generated as described^[@CR41]^. Amplicons of the viral genomes were generated as follows: for whole-genome sequencing (amplicons 1--13) and partial-genome sequencing (amplicons A--G, X and Y), the primer pairs indicated in [Supplementary Table 4](#MOESM2){ref-type="media"} were used in a 50-μl PCR reaction using Phusion polymerase (New England BioLabs). Five microliters of each PCR reaction were electrophoresed on agarose gels to verify the presence of correctly sized amplicons, and PCR products were purified using a Qiagen PCR Purification Kit (Qiagen, Valencia, CA, USA). Amplicons were then sequenced using the corresponding primer sets for each amplicon, as indicated in [Supplementary Table 4](#MOESM2){ref-type="media"}. Sequence results were analyzed using Geneious Pro 5.3.6 (Biomatters, Auckland, New Zealand) and Serial Cloner 2.1 (SerialBasics, <http://serialbasics.free.fr/Home/Home.html>).

Statistical analyses. {#Sec19}
---------------------

Statistical analyses were performed using the Mann-Whitney *U* test (<http://elegans.som.vcu.edu/~leon/stats/utest.html>). Significance was set at *P* \< 0.05.

Accession codes. {#Sec20}
----------------

Plaque-purified MA-ExoN isolate sequences are deposited in GenBank under the following accession codes: [FJ882942](http://www.ncbi.nlm.nih.gov/nuccore/?term=FJ882942); [FJ882943](http://www.ncbi.nlm.nih.gov/nuccore/?term=FJ882943); [FJ882945](http://www.ncbi.nlm.nih.gov/nuccore/?term=FJ882945); [FJ882948](http://www.ncbi.nlm.nih.gov/nuccore/?term=FJ882948); [FJ882951](http://www.ncbi.nlm.nih.gov/nuccore/?term=FJ882951); [FJ882952](http://www.ncbi.nlm.nih.gov/nuccore/?term=FJ882952); [FJ882953](http://www.ncbi.nlm.nih.gov/nuccore/?term=FJ882953); [FJ882957](http://www.ncbi.nlm.nih.gov/nuccore/?term=FJ882957); [FJ882958](http://www.ncbi.nlm.nih.gov/nuccore/?term=FJ882958); [FJ882959](http://www.ncbi.nlm.nih.gov/nuccore/?term=FJ882959); [FJ882961](http://www.ncbi.nlm.nih.gov/nuccore/?term=FJ882961); [FJ882962](http://www.ncbi.nlm.nih.gov/nuccore/?term=FJ882962); [HQ890526](http://www.ncbi.nlm.nih.gov/nuccore/?term=HQ890526); [HQ890527](http://www.ncbi.nlm.nih.gov/nuccore/?term=HQ890527); [HQ890528](http://www.ncbi.nlm.nih.gov/nuccore/?term=HQ890528); [HQ890529](http://www.ncbi.nlm.nih.gov/nuccore/?term=HQ890529); [HQ890530](http://www.ncbi.nlm.nih.gov/nuccore/?term=HQ890530); [HQ890531](http://www.ncbi.nlm.nih.gov/nuccore/?term=HQ890531); [HQ890532](http://www.ncbi.nlm.nih.gov/nuccore/?term=HQ890532); [HQ890533](http://www.ncbi.nlm.nih.gov/nuccore/?term=HQ890533); [HQ890534](http://www.ncbi.nlm.nih.gov/nuccore/?term=HQ890534); [HQ890535](http://www.ncbi.nlm.nih.gov/nuccore/?term=HQ890535); [HQ890536](http://www.ncbi.nlm.nih.gov/nuccore/?term=HQ890536); [HQ890537](http://www.ncbi.nlm.nih.gov/nuccore/?term=HQ890537); [HQ890538](http://www.ncbi.nlm.nih.gov/nuccore/?term=HQ890538); [HQ890539](http://www.ncbi.nlm.nih.gov/nuccore/?term=HQ890539); [HQ890540](http://www.ncbi.nlm.nih.gov/nuccore/?term=HQ890540); [HQ890541](http://www.ncbi.nlm.nih.gov/nuccore/?term=HQ890541); [HQ890542](http://www.ncbi.nlm.nih.gov/nuccore/?term=HQ890542); [HQ890543](http://www.ncbi.nlm.nih.gov/nuccore/?term=HQ890543); [HQ890544](http://www.ncbi.nlm.nih.gov/nuccore/?term=HQ890544); [HQ890545](http://www.ncbi.nlm.nih.gov/nuccore/?term=HQ890545); [HQ890546](http://www.ncbi.nlm.nih.gov/nuccore/?term=HQ890546); [JF292902](http://www.ncbi.nlm.nih.gov/nuccore/?term=JF292902); [JF292903](http://www.ncbi.nlm.nih.gov/nuccore/?term=JF292903); [JF292904](http://www.ncbi.nlm.nih.gov/nuccore/?term=JF292904); [JF292905](http://www.ncbi.nlm.nih.gov/nuccore/?term=JF292905); [JF292906](http://www.ncbi.nlm.nih.gov/nuccore/?term=JF292906); [JF292907](http://www.ncbi.nlm.nih.gov/nuccore/?term=JF292907); [JF292908](http://www.ncbi.nlm.nih.gov/nuccore/?term=JF292908); [JF292909](http://www.ncbi.nlm.nih.gov/nuccore/?term=JF292909); [JF292910](http://www.ncbi.nlm.nih.gov/nuccore/?term=JF292910); [JF292911](http://www.ncbi.nlm.nih.gov/nuccore/?term=JF292911); [JF292912](http://www.ncbi.nlm.nih.gov/nuccore/?term=JF292912); [JF292913](http://www.ncbi.nlm.nih.gov/nuccore/?term=JF292913); [JF292914](http://www.ncbi.nlm.nih.gov/nuccore/?term=JF292914); [JF292915](http://www.ncbi.nlm.nih.gov/nuccore/?term=JF292915); [JF292916](http://www.ncbi.nlm.nih.gov/nuccore/?term=JF292916); [JF292917](http://www.ncbi.nlm.nih.gov/nuccore/?term=JF292917); [JF292918](http://www.ncbi.nlm.nih.gov/nuccore/?term=JF292918); [JF292919](http://www.ncbi.nlm.nih.gov/nuccore/?term=JF292919); and [JF292920](http://www.ncbi.nlm.nih.gov/nuccore/?term=JF292920).
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